DNMT1 and chronic myelomonocytic leukemia: Indeed, 5-azacytidine (or azacytidine (5-aza, Vidaza®)) and 5-aza-2′-deoxycytidine (or decitabine (DAC, Dacogen®)) are two DNMT inhibitors approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML) [30,57,58].